scholarly journals A case report of anaplastic thyroid cancer and papillary thyroid cancer lymph node metastasis: An unusual presentation as an invasive hypopharyngeal mass

2021 ◽  
Author(s):  
Veena Vishwanath ◽  
Nichola Gaunt ◽  
Durgesh Rana ◽  
Dominic St Leger ◽  
Michael Dykes ◽  
...  

Anaplastic thyroid carcinoma is a rare undifferentiated tumour of the thyroid follicular epithelium. It almost always develops from a pre-existing well-differentiated thyroid cancer with a co-existent thyroid malignancy varying from 5-17% . The co-existence of papillary thyroid cancer (PTC) with anaplastic thyroid cancer is a rare occurrence in metastases outside the primary thyroid lesion. Traditionally, this has been regarded as an aggressive form of cancer associated with a dismal prognosis. Recently the focus has shifted to the development of novel therapies based on the availability of comprehensive genomic profiling platforms (CGP) with a rapid turn-around to identify molecular aberrations in tumours which acts as potential therapeutic targets. In the United Kingdom, we report the case of a 60-year old woman with an unusual presentation of (metastatic) ATC and concomitant papillary thyroid cancer metastasis within a contralateral lymph node. This was initially perceived as a left pyriform fossa mass involving and compressing her left hemi-larynx on clinical and radiological examination. Following the identification of BRAF V600E mutation on CGP, she was started on targeted therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib and demonstrated excellent clinical and radiological response following 7 months of treatment. She has subsequently undergone total thyroidectomy alongside with bilateral neck dissection, and is due to start radio-active iodine treatment to reduce the risk of recurrence of disease.

2012 ◽  
Vol 20 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Gina M. Howell ◽  
Marina N. Nikiforova ◽  
Sally E. Carty ◽  
Michaele J. Armstrong ◽  
Steven P. Hodak ◽  
...  

2020 ◽  
Vol 36 (3) ◽  
pp. 249-255
Author(s):  
Samet Sahin ◽  
Gul Daglar ◽  
Ebru Menekse ◽  
Busranur Cavdarli ◽  
Tolga Baglan

Author(s):  
Yubing Tao ◽  
Fei Wang ◽  
Xiaopei Shen ◽  
Guangwu Zhu ◽  
Rengyun Liu ◽  
...  

Abstract Context How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. Objective To study whether BRAF V600E affected LNM-associated mortality in PTC. Design, Setting, Participants We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 (IQR 35–58) years and median follow-up time of 58 (IQR 26–107) months. Results Overall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAFV600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAFV600E patients; mortality rates were 2/659 (0.3%) versus 4/321 (1.2%) in non-LNM versus LNM patients (P=0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAFV600E CPTC, morality rates were 7/515 (1.4%) versus 28/363 (7.7%) in non-LNM versus LNM patients (P<0.001), corresponding to HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAFV600E versus absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism. Conclusions LNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance.


2014 ◽  
Author(s):  
Merve Yilmaz ◽  
Arzu Gedik ◽  
Ahmet Omer Ikiz ◽  
Tugba Gumus ◽  
Mehmet Calan ◽  
...  

2020 ◽  
Vol 9 (10) ◽  
pp. 999-1008
Author(s):  
Pan Chen ◽  
Liqin Pan ◽  
Wensi Huang ◽  
Huijuan Feng ◽  
Wei Ouyang ◽  
...  

Objective To evaluate the relationship between the BRAF V600E mutation in lymph node metastasis (LNM) and its invasive characteristics in papillary thyroid cancer (PTC). Material and methods A total of 373 PTC patients were enrolled in this study conducted at Zhujiang Hospital of Southern Medical University between January 2017 and December 2018. PTCs with cervical lymph node metastases were verified pathohistologically, and primary tumors and LNM were examined for the BRAF V600E mutation. Patients were excluded from the study if the BRAF V600E mutation was examined only in primary tumors or only in LNM. Results Of the 373 patients examined, BRAF V600E mutation frequency in primary tumors was slightly higher than in LNM (81.5% vs 78.0%, P = 0.000), the intra-class correlation coefficient (ICC) was 0.865 (95% CI 0.835–0.890). The BRAF V600E mutation in both primary tumor and LNM negatively correlated with the size of the largest metastatic focus of LNM (Odds ratio, OR = 0.297, 95% CI 0.143–0.616, P = 0.001; OR = 0.242, 95% CI 0.119–0.492, P = 0.000, respectively). There was no relationship between BRAF V600E mutation in LNM and the number, extranodal extension or stage of LNM (P > 0.05). Conclusion The BRAF V600E mutation in LNM may not be related to the invasive characteristics of LNM in PTC.


2018 ◽  
Author(s):  
Iva Jakubikova ◽  
Elin Schoultz ◽  
Ellen Johansson ◽  
Shawn Liang ◽  
Konrad Patyra ◽  
...  

2019 ◽  
Vol 26 (4) ◽  
pp. 461-470 ◽  
Author(s):  
Xuan Su ◽  
Li-Wen Lin ◽  
Jie-Ling Weng ◽  
Shu-Wei Chen ◽  
Xin-Hua Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document